TI 061

Drug Profile

TI 061

Alternative Names: TI-061

Latest Information Update: 23 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tioma Therapeutics
  • Developer Arch Oncology
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD47 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 23 Jan 2018 Tioma Therapeutics is now called Arch Oncology
  • 13 Oct 2017 Tioma Therapeutics terminates a phase I/II trial in Solid tumours (Late-stage disease, Monotherapy, Combination therapy, In adults, In the elderly) in United Kingdom (EudraCT2016-004372-22)
  • 16 Jun 2017 Tioma Therapeutics has intellectual property rights for anti-CD47 antibodies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top